BioIVT, Kansas City, supports the local life science community by enabling smarter science and accelerating medical breakthroughs through high-quality, personalized biospecimen solutions and research services. For more than 25 years, the Kansas City scientists have lent their strong expertise in in vitro research to supporting drug developers.

BioIVT specializes in control and disease-state research support, including human and animal tissues and specimen preparations, ADME-Tox products and services, immune cell products, blood, cerebrospinal and other biofluids. The subcellular fraction center of excellence in Kansas City manufactures hepatocytes and subcellular fractions, and its deep bench of scientists provides tailored in vitro ADME contract research solutions throughout the United States, Europe and Asia.

With a global footprint and a commitment to quality, BioIVT partners with researchers to provide the biological materials and data necessary to support their drug discovery and development goals.

Catalent is a leading global Contract Development and Manufacturing Organization (CDMO), trusted by pharma, biotech and self-care companies to accelerate the development, manufacturing and delivery of products that improve lives.

With advanced technologies, deep expertise and a worldwide network, Catalent partners with innovators to transform bold ideas into life-changing therapies and self-care solutions.

Catalent’s Kansas City facility is home to our Oral & Specialty Drug Delivery, Biologics Analytical Services and Clinical Supply Services businesses.

Oral & Specialty Drug Delivery
The site provides a range of integrated services for oral solid dosage forms, from formulation development and analytical testing to clinical and commercial-scale manufacture.  The facility is the commercial manufacturing Center-of-Excellence for accelerated development programs and roller compaction.

Biologics Analytical Services
The Kansas City facility is also a Center-of-Excellence for our Biologics Analytical Services business. Our large molecule analytical team has over 25 years of experience providing broad-based and orthogonal analytical CMC services for stand-alone and integrated biologics projects.  We provide support for drug substance, drug product, and intermediates for both innovator and biosimilar/biobetter products.

Clinical Supply Services
Our facility also offers comprehensive clinical packaging services including clinical supply management, package engineering, clinical manufacturing, primary and secondary packaging, global distribution and logistics, and return/destruction services. The facility features an isolated potent suite and DEA Schedule I-V controlled drug storage to handle even your most challenging products.

With a strong U.S. presence in research, manufacturing, and field support, Ceva Animal Health plays a vital role in strengthening animal well-being nationwide, delivering innovative vaccines, therapeutics, and behavioral health solutions that support veterinarians, farmers, and pet owners.

Charles River is dedicated to helping you accelerate research and drug development—because every moment matters. Their essential products and services empower pharmaceutical, biotech, government, and academic teams to turn possibilities into breakthroughs. From discovery to early development and safe manufacturing, they provide the solutions you need to bring new therapies to patients faster.

ELIAS Animal Health is a medical biotechnology company focused on advancing a pipeline of immunotherapies, including an adoptive cell therapy and an oncolytic virotherapy, for the treatment of canine cancers. The company’s therapeutic pipeline offers the prospect of improved clinical outcomes and the potential for fundamentally changing the way cancer is treated.

Eurofins Viracor BioPharma partners with biopharmaceutical sponsors to advance Phase I–IV clinical trials through specialized testing, custom assay development, and scientific expertise. Backed by more than 40 years of experience and an extensive portfolio of 3,000+ validated assays, we deliver high-quality, actionable data across infectious disease, immunology, biomarker, vaccine, and cell-based testing programs. Our flexible, science-driven approach helps sponsors overcome complex development challenges, make informed decisions, and accelerate promising therapies toward patients.

Hill’s Pet Nutrition leads the way in several scientific fields to create the quality nutrition your pet deserves.

KCAS Bio is a global CRO supporting bioanalytical and drug development programs from late discovery through commercialization and final regulatory submission. With more than 45 years of experience in drug development, KCAS Bio has built proven expertise across a wide range of disease and therapeutic areas. The company supports both established and advanced modalities, leveraging highly technical platforms designed for complex therapies. Approximately 87% of KCAS Bio’s work today involves advanced modalities, reflecting a growing demand for its specialized capabilities. Across all programs, the organization is recognized for its consistency, transparency, and unwavering commitment to data integrity at every stage of development.

As KCAS Bio’s capabilities have expanded, the company has developed differentiated engagement strategies tailored to the distinct needs of each segment; from highly resourced global sponsors to innovative biotechs that may later transition into public companies.

KCAS Bio operates with four locations worldwide, employing nearly 400 scientists and professionals across its network of laboratory sites located in Kansas City; the greater Philadelphia, PA area; Lyon, France; and Melbourne, Australia. In the Kansas City region specifically, the company maintains a 70,000 sq.ft. lab facility in Olathe, KS and employs approximately 300 team members, making it a significant contributor to the local life sciences workforce while also serving a broad international client base.

KCAS Bio has been an active part of the Kansas City life sciences ecosystem since 1979 and embarked on a focused growth initiative beginning in 2016. With a robust ecosystem of other CRO and CDMO organizations in the Kansas City metro, KCAS Bio has called KC home since its inception. The available talent and CRO/CDMO landscape have created a solid talent base, and along with the region’s universities, KC is a very attractive place for growing this segment. Kansas City’s collaborative environment and long-standing commitment to bioscience innovation have enabled KCAS Bio to scale its operations while maintaining scientific excellence and operational reliability.

Serving the scientific community since 1925, Labconco Corporation designs and manufactures premium laboratory equipment that supports scientific discovery and innovation. Our product portfolio includes a wide variety of fume hoods, biological safety cabinets, freeze dryers, evaporators, glassware washers, water purification systems, glove boxes, and laboratory animal research products. Through our global network of distributors, we serve customers in academia, healthcare, biotechnology, pharmaceutical, industrial, and government laboratories worldwide.

Latham BioPharm Group (LBG) is a leading life sciences consulting company that works with pharmaceutical, biotech, CROs, academia, and medical device/diagnostic companies alike to solve complex business, regulatory, and product development challenges.

Since 1996, they have helped life sciences companies—both large and small—drive long-term value into their organizations. Core services include:

• Product Development: comprehensive, functional expertise in vaccines, therapeutics, cell and gene therapies, and medical devices/diagnostics
• Non-Dilutive Funding: turnkey services from initial positioning within a U.S. Government Agency/Non-Governmental Organization (NGO), to proposal development, to back-end program support, and everything in between
• Strategic Consulting: full complement of capabilities supporting critical organization decision-making

Likarda is a biotechnology company developing advanced biomaterial and encapsulation technologies that improve the delivery, storage, and performance of cells, biologics, and therapeutic compounds. Its proprietary hydrogel and polymer platforms are designed to protect fragile living cells and sensitive drugs from environmental stress, enhance stability, and provide controlled release at the target site. By solving long-standing challenges in formulation and transport, Likarda helps researchers and biopharma companies accelerate development while improving consistency, potency, and product shelf life.

A major focus of Likarda’s innovation is reducing dependence on costly and complex cold-chain logistics such as liquid nitrogen storage and shipping. Through biostabilization and protective encapsulation, the company enables more practical, scalable, and sustainable approaches for regenerative medicine, cell therapy, and advanced drug delivery. Based in Kansas City, Likarda combines deep scientific expertise with practical commercialization strategies to bring next-generation therapies closer to patients, researchers, and industry partners worldwide.

Love Lifesciences is committed to revolutionizing the future of injectable therapies in the compounding pharmacy market. Their flagship innovation, The UNIPEN Injection Platform, is the first therapeutic-agnostic injection system designed to optimize compounding pharmacy efficiency, patient safety, and overall precision across a wide and diverse range of injectable therapies. They’re helping compounding pharmacies work smarter to meet & exceed a rapidly-growing patient population.

Phoreus Biotechnology, Inc. is the provider of a proprietary technology platform with the capacity to revolutionize global One Health. Their Branched Amphipathic Peptide Capsules™ (BAPC™) offer substantially increased efficacy in the creation and delivery of novel vaccines, cancer therapies, alternative antibiotics and biopesticides for improved human, animal, plant and environmental health around the world.

Ronawk exists to let biology be biology and to empower innovators building the next generation of therapies. Most cell culture tools were not designed for human biology. They were built for simpler systems, not for the thousands of specialized mammalian cells that form our bodies.

Ronawk’s Bio-OS™ is an operating system for mammalian cells built from three connected layers: modular hardware, standardized operations, and living wetware. Its foundation is Bio-Blocks®, modular hydrogel substrates that provide cells with the structure and environment they need to interact, communicate, and organize more like they do in the human body. Standardized processes then create an operational layer that allows Bio-Blocks and cells to be combined for a wide range of research, development, and manufacturing applications. The final layer is the wetware, where living cells activate the system by forming sophisticated tissue-like structures and secreting valuable biologics.

This modular design is why Bio-OS has been used to cultivate more than 100 different mammalian cell types. By combining structure, process, and living biology, Bio-OS helps close the gap between discovery and manufacturing, giving innovators a more consistent, reliable, and scalable way to grow the cells and biologics they need.

T3SSIMUNE is combining two innovative technologies to create a single vaccine that broadly protects against a range of bacterial strains. Live-attenuated vaccines generally protect against only one or two strains of bacteria. By targeting the shared common characteristics between all serotypes, they can encourage the body to produce antibodies that defend against many more.

It sounds simple but it’s actually a complex platform involving a protein fragment antigen complex and a nanoparticle delivery system. To make it happen, T3SSIMUNE researchers are applying their specialized experience in vaccines and microbiology.